New digital iTalkBetter app significantly improves speech in stroke patients
Aphasia is a language disorder caused by some form of brain damage, including stroke
Read Moreby Jen Brogan | Feb 29, 2024 | News | 0
Aphasia is a language disorder caused by some form of brain damage, including stroke
Read Moreby John Pinching | May 24, 2022 | News | 0
Less invasive procedure offers an equally effective alternative for heart condition patients
Read Moreby John Pinching | Feb 28, 2022 | News | 0
Unmet need among over 7000 rare diseases is being addressed in a comprehensive action plan
Read Moreby Lucy Parsons | Aug 17, 2021 | News | 0
NIHR trial shows the lung drug could treat heart failure patients
Read Moreby Lucy Parsons | Jun 29, 2021 | News | 0
Mixing different vaccines produces a strong immune response against virus, according to researchers
Read Moreby Lucy Parsons | Jun 18, 2021 | News | 0
NHSX and Accelerated Access Collaborative (AAC) have backed 38 AI-driven research projects
Read Moreby Selina McKee | Jun 9, 2021 | News | 0
The NIHR-supported RECOVERY trial found that the anti-inflammatory drug does not improve survival for hospitalised patients with COVID-19
Read Moreby Selina McKee | May 20, 2021 | News | 0
Initial results trialling seven vaccines will inform plans for Autumn booster programme
Read Moreby Selina McKee | Apr 7, 2021 | News | 0
The NIHR-funded trial will assess whether removing small fibroids and endometrial polyps improves fertility and live births
Read Moreby Lucy Parsons | Nov 13, 2020 | News | 0
Research centres will accelerate development of late-stage research within NHS
Read Moreby Selina McKee | Nov 2, 2020 | News | 0
It is hoped that findings from the NIHR-funded trial will help better inform treatment decisions
Read Moreby Lucy Parsons | Oct 30, 2020 | News | 0
Findings come from new research funded by Cancer Research UK and NIHR
Read MorePharmaTimes Media Ltd.
Mansard House
Church Road
Little Bookham
Leatherhead
Surrey KT23 3JG
E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999
F: +44 (0)20 7240 4479